Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology

Core Insights - Ventripoint Diagnostics Ltd. has signed a non-binding term sheet with Lishman Global Inc. for an exclusive license of its technology for use in Lishman's echocardiography image platform in China, including Hong Kong and Macao [1][3] - Lishman's subsidiary in China has received CFDA approval for the VMS+ product, which analyzes the right ventricle of the heart, and has a GMP certified manufacturing facility capable of meeting market demands [2][3] - The new license will allow Lishman to integrate VMS+ 4.0 into its echocardiography platforms and market the technology in the region, with a commitment to invest in Ventripoint [3][4] Company Developments - Ventripoint's VMS products utilize proprietary knowledge-based reconstruction technology, providing accurate volumetric cardiac measurements comparable to MRI, which enhances cardiologists' confidence in patient management [7] - The company is focused on improving healthcare outcomes in China, where heart disease is a significant issue, with a higher rate of echocardiogram usage compared to North America [4][5] - Lishman Global aims to establish a presence in all 22 provinces and Special Administrative Regions of China, targeting over 32,000 hospitals, including 2,500 Tier 1 hospitals [5][6] Market Context - The partnership is expected to enhance the availability of advanced echocardiography solutions in China, where there is a growing demand for accurate cardiac imaging technologies [4][5] - The integration of VMS+ is anticipated to improve the accuracy of echo studies and reduce the need for repeat studies, addressing a critical healthcare need in the region [4][7]